Home/Pipeline/BAN0805

BAN0805

Parkinson's Disease

PreclinicalResearch

Key Facts

Indication

Parkinson's Disease

Phase

Preclinical

Status

Research

Company

bioarctic-ab

About bioarctic-ab

BioArctic AB is a research-intensive Swedish biopharma focused on translating novel insights into protein aggregation pathology into transformative treatments for neurodegenerative diseases. Its strategic triumph is the Eisai-partnered anti-amyloid beta protofibril antibody lecanemab (Leqembi®), which achieved FDA approval in 2023, validating the company's core scientific thesis. The company's strategy balances revenue from this landmark partnership with advancing a wholly-owned pipeline targeting alpha-synuclein in Parkinson's disease, leveraging its proprietary BrainTransporter® platform to enhance drug delivery to the brain. With a market cap nearing $28 billion, BioArctic stands as a premier European biotech success story.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease ALS Multiple System Atrophy

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active